SMT201600271B - BENZOSSAZEPINONI FUSI COME MODULATORI DI CANALl IONICI - Google Patents

BENZOSSAZEPINONI FUSI COME MODULATORI DI CANALl IONICI

Info

Publication number: SMT201600271B
Authority: SM; San Marino
Prior art keywords: ionici; canonal; benzossazepinoni; fusi; modulators
Prior art date: 2011-07-01

Application number

SM201600271T

Other languages

English (en)

Inventor

Britton Kenneth Corkey

Elfatih Elzein

Robert H Jiang

Rao V Kalla

Dmitry Koltun

Xiaofen Li

Ruben Martinez

Eric Q Parkhill

Thao Perry

Jeff Zablocki

Chandrasekar Venkataramani

Michael Graupe

Juan Guerrero

Original Assignee

Gilead Sciences Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-07-01

Filing date

2016-08-08

Publication date

2016-08-31

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46513866&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SMT201600271(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2016-08-08 Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc

2016-08-31 Publication of SMT201600271B publication Critical patent/SMT201600271B/it

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
- C07D243/16—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
- C07D243/18—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals substituted in position 2 by nitrogen, oxygen or sulfur atoms
- C07D243/24—Oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D267/02—Seven-membered rings
- C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D267/02—Seven-membered rings
- C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
- C07D267/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D267/14—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D291/00—Heterocyclic compounds containing rings having nitrogen, oxygen and sulfur atoms as the only ring hetero atoms
- C07D291/08—Heterocyclic compounds containing rings having nitrogen, oxygen and sulfur atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D419/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms
- C07D419/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D419/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Diabetes (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Epidemiology (AREA)
Pain & Pain Management (AREA)
Endocrinology (AREA)
Rheumatology (AREA)
Obesity (AREA)
Hematology (AREA)
Emergency Medicine (AREA)
Urology & Nephrology (AREA)
Pulmonology (AREA)
Vascular Medicine (AREA)
Hospice & Palliative Care (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Physical Or Chemical Processes And Apparatus (AREA)
Photoreceptors In Electrophotography (AREA)
Television Systems (AREA)

SM201600271T 2011-07-01 2016-08-08 BENZOSSAZEPINONI FUSI COME MODULATORI DI CANALl IONICI SMT201600271B (it)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201161503980P	2011-07-01	2011-07-01
US201161582160P	2011-12-30	2011-12-30
PCT/US2012/045086 WO2013006485A1 (en)	2011-07-01	2012-06-29	Fused benzoxazepinones as ion channel modulators

Publications (1)

Publication Number	Publication Date
SMT201600271B true SMT201600271B (it)	2016-08-31

Family

ID=46513866

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SM201600271T SMT201600271B (it)	2011-07-01	2016-08-08	BENZOSSAZEPINONI FUSI COME MODULATORI DI CANALl IONICI

Country Status (38)

Country	Link
US (5)	US8586732B2 (it)
EP (6)	EP3101013B1 (it)
JP (2)	JP5889407B2 (it)
KR (2)	KR101608927B1 (it)
CN (2)	CN103857659B (it)
AP (1)	AP2013007300A0 (it)
AR (1)	AR086828A1 (it)
AU (1)	AU2012279236B2 (it)
BR (1)	BR112013032361A2 (it)
CA (1)	CA2838223A1 (it)
CL (1)	CL2013003598A1 (it)
CO (1)	CO6821960A2 (it)
CR (1)	CR20130658A (it)
CY (1)	CY1117915T1 (it)
DK (1)	DK2726466T3 (it)
EA (2)	EA027356B1 (it)
EC (1)	ECSP13013083A (it)
ES (6)	ES2790633T3 (it)
HK (5)	HK1225726A1 (it)
HR (1)	HRP20160952T1 (it)
HU (1)	HUE029398T2 (it)
IL (2)	IL230022B (it)
MD (1)	MD4371C1 (it)
ME (1)	ME02546B (it)
MX (1)	MX336810B (it)
NZ (2)	NZ618691A (it)
PE (1)	PE20140690A1 (it)
PH (1)	PH12013502549B1 (it)
PL (1)	PL2726466T3 (it)
PT (1)	PT2726466T (it)
RS (1)	RS55024B1 (it)
SI (1)	SI2726466T1 (it)
SM (1)	SMT201600271B (it)
TW (4)	TW201837023A (it)
UA (1)	UA115529C2 (it)
UY (1)	UY34171A (it)
WO (1)	WO2013006485A1 (it)
ZA (1)	ZA201308981B (it)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TWI598347B (zh)	2009-07-13	2017-09-11	基利科學股份有限公司	調節細胞凋亡信號之激酶的抑制劑
EA025824B1 (ru) *	2009-07-27	2017-02-28	Джилид Сайэнс, Инк.	Конденсированные гетероциклические соединения в качестве модуляторов ионных каналов
ES2529119T3 (es)	2010-07-02	2015-02-17	Gilead Sciences, Inc.	Compuestos heterocíclicos condensados como moduladores de canales iónicos
KR20140033377A (ko)	2011-05-10	2014-03-18	길리애드 사이언시즈, 인코포레이티드	나트륨 채널 조절제로서의 융합된 헤테로시클릭 화합물
TW201837023A (zh)	2011-07-01	2018-10-16	美商基利科學股份有限公司	作為離子通道調節劑之稠合雜環化合物
NO3175985T3 (it)	2011-07-01	2018-04-28
US9040678B2 (en)	2011-08-05	2015-05-26	Illumina, Inc.	Functionalization and purification of molecules by reversible group exchange
UY34573A (es)	2012-01-27	2013-06-28	Gilead Sciences Inc	Inhibidor de la quinasa que regula la señal de la apoptosis
AU2013203252B2 (en) *	2012-01-27	2015-08-20	Gilead Sciences, Inc.	Combination therapies using late sodium ion channel blockers and potassium ion channel blockers
JP6426694B2 (ja)	2013-03-15	2018-11-21	グローバルブラッドセラピューティクスインコーポレイテッド	ヘモグロビンの修飾のための化合物及びその使用
US20140329755A1 (en) *	2013-05-01	2014-11-06	Gilead Sciences, Inc.	Combination therapy for the treatment of arrhythmias or heart failure
KR20160035060A (ko)	2013-08-01	2016-03-30	길리애드 사이언시즈, 인코포레이티드	비대성 심근병증을 치료하는 방법
JP2016525580A (ja) *	2013-08-01	2016-08-25	ギリアードサイエンシーズ，インコーポレイテッド	Ｑｔ延長症候群を処置するための化合物および方法
RU2016113156A (ru) *	2013-09-10	2017-10-16	Хромоселл Корпорейшн	Модуляторы натриевого канала для лечения боли и диабета
EA202092627A1 (ru)	2013-11-18	2021-09-30	Глобал Блад Терапьютикс, Инк.	Соединения и их применения для модуляции гемоглобина
AU2014364783B2 (en)	2013-12-19	2017-01-05	Gilead Sciences, Inc.	Fused heterocyclic compounds as ion channel modulators
CN104844535A (zh)	2014-02-13	2015-08-19	吉利德科学公司	用于制备稠合杂环离子通道调节剂的方法
TW201613908A (en) *	2014-02-13	2016-04-16	Gilead Sciences Inc	Solid forms of an ion channel modulator
WO2015153153A1 (en) *	2014-04-02	2015-10-08	Gilead Sciences, Inc.	Methods of treating patients having implantable cardiac devices
KR20190035960A (ko)	2014-09-24	2019-04-03	길리애드 사이언시즈, 인코포레이티드	간 질환의 치료 방법
SG11201704738UA (en)	2014-12-23	2017-07-28	Gilead Sciences Inc	Processes for preparing ask1 inhibitors
MA41252A (fr)	2014-12-23	2017-10-31	Gilead Sciences Inc	Formes solides d'un inhibiteur d'ask 1
MX380753B (es)	2015-07-02	2025-04-01	Hoffmann La Roche	Lactamas bicíclicas y métodos de uso de las mismas.
US20170007617A1 (en) *	2015-07-09	2017-01-12	Gilead Sciences Drive	Intravenous formulations of a late sodium current inhibitor
KR102808827B1 (ko)	2016-02-05	2025-05-19	데날리 테라퓨틱스 인크.	수용체-상호작용 단백질 키나제 1의 억제제
WO2017205536A2 (en) *	2016-05-24	2017-11-30	Genentech, Inc.	Therapeutic compounds and uses thereof
AU2017310526B2 (en)	2016-08-12	2021-08-12	Edwin J. Iwanowicz	Protein kinase regulators
US20180064726A1 (en) *	2016-09-08	2018-03-08	Auspex Pharmaceuticals, Inc.	Deuterium-Substituted Oxazepin Compounds
EP3526219B1 (en)	2016-10-17	2021-12-15	F. Hoffmann-La Roche AG	Bicyclic pyridone lactams and methods of use thereof
AR110252A1 (es)	2016-11-30	2019-03-13	Gilead Sciences Inc	Compuestos heterocíclicos fusionados como inhibidores de la quinasa cam
DK3552017T3 (da)	2016-12-09	2022-05-16	Denali Therapeutics Inc	Forbindelser, der er anvendelige som ripk1-inhibitorer
US20200085838A1 (en) *	2017-05-16	2020-03-19	Praxis Precision Medicines, Inc.	Methods of treating epilepsy and neurodevelopmental disorders
MY200328A (en)	2017-05-17	2023-12-20	Denali Therapeutics Inc	Kinase inhibitors and uses thereof
TWI795440B (zh)	2017-09-15	2023-03-11	美商佛瑪治療公司	作為ＣＢＰ／ｐ３００抑制劑之四氫─咪唑並喹啉化合物
WO2019168874A1 (en)	2018-02-27	2019-09-06	The Research Foundation For The State University Of New York	Difluoromethoxylation and trifluoromethoxylation compositions and methods for synthesizing same
US11649218B2 (en)	2018-03-09	2023-05-16	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	C-Abl tyrosine kinase inhibitory compound embodiments and methods of making and using the same
MX2023013508A (es)	2018-06-29	2023-12-13	Forma Therapeutics Inc	Inhibicion de la proteina de union a creb (cbp).
EP3870173A4 (en)	2018-10-24	2022-06-22	Vanderbilt University	WDR5 INHIBITORS AND MODULATORS
KR102172595B1 (ko)	2018-12-19	2020-11-02	인하대학교 산학협력단	벤조옥사제핀 유도체 화합물을 포함하는 비만 예방 또는 치료용 약학 조성물
AR118362A1 (es)	2019-03-15	2021-09-29	Forma Therapeutics Inc	Inhibición de la proteína de unión al elemento de respuesta a amp cíclico (creb)
CN109879830A (zh) *	2019-03-27	2019-06-14	安徽师范大学	一种含环外双键的氧氮杂环庚烷衍生物及其制备方法
US20220242849A1 (en) *	2019-06-04	2022-08-04	Vanderbilt University	Wdr5 inhibitors and modulators
US11801243B2 (en)	2020-09-23	2023-10-31	Forma Therapeutics, Inc.	Bromodomain inhibitors for androgen receptor-driven cancers
US11795168B2 (en)	2020-09-23	2023-10-24	Forma Therapeutics, Inc.	Inhibiting cyclic amp-responsive element-binding protein (CREB) binding protein (CBP)
IL305119A (en)	2021-02-19	2023-10-01	Sudo Biosciences Ltd	Tyk2 inhibitors and uses thereof
TW202246232A (zh)	2021-02-19	2022-12-01	英商蘇多生物科學有限公司	Ｔｙｋ２抑制劑及其用途
WO2023137035A1 (en)	2022-01-12	2023-07-20	Denali Therapeutics Inc.	Crystalline forms of (s)-5-benzyl-n-(5-methyl-4-oxo-2, 3,4,5- tetrahydropyrido [3,2-b] [l,4]oxazepin-3-yl)-4h-l,2,4-triazole-3-carboxamide
CN118556044A (zh) *	2022-01-29	2024-08-27	江苏恒瑞医药股份有限公司	稠杂环类化合物、其制备方法及其在医药上的应用
EP4495119A4 (en)	2022-03-16	2025-06-25	Jiangsu Hengrui Pharmaceuticals Co., Ltd.	FUSED HETEROCYCLIC COMPOUND, PREPARATION METHOD AND MEDICAL USE THEREOF
PE20251873A1 (es) *	2022-04-22	2025-07-22	Teijin Pharma Ltd	Derivado de oxazepina

Family Cites Families (225)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2867618A (en)	1957-02-14	1959-01-06	Dow Chemical Co	3, 4-dihydro-2h-1, 3-benzoxazine
US2826575A (en)	1957-05-06	1958-03-11	Dow Chemical Co	3, 3'-alkylenebis
NL128591C (it)	1965-07-02
US3441649A (en)	1966-08-18	1969-04-29	Univ Minnesota	Suppression of cardiac ventricular fibrillation and cardiac arrhythmias with bretylium tosylate
US3594372A (en)	1968-08-13	1971-07-20	American Home Prod	Pyrimido(4,5-e)(1,4)oxazepin-5-ones and derivatives thereof
US3845770A (en)	1972-06-05	1974-11-05	Alza Corp	Osmatic dispensing device for releasing beneficial agent
US4062881A (en)	1974-07-26	1977-12-13	Cincinnati Milacron Chemicals, Inc.	Sulfide containing tin stabilizers
US4230705A (en)	1976-09-22	1980-10-28	American Cyanamid Company	6-Phenyl-1,2,4-triazolo[4,3-b]pyridazines and their uses in treating anxiety
US4242515A (en)	1979-03-28	1980-12-30	American Cyanamid Company	Substituted 3-alkyl-6-phenyl-1,2,4-triazolo-[4,3-a]pyridines
US4244953A (en)	1979-10-24	1981-01-13	American Cyanamid Company	Substituted 6-phenyl-5,6,7,8-tetrahydro-1,2,4-triazolo-[4,3-a]pyridines
JPS5675428A (en)	1979-11-21	1981-06-22	Ayanori Takabe	Hypoglycemic agent containing procainamide hydrochloride
US4326525A (en)	1980-10-14	1982-04-27	Alza Corporation	Osmotic device that improves delivery properties of agent in situ
US4812565A (en) *	1982-09-30	1989-03-14	A. H. Robins Company, Incorporated	Fused aromatic oxazepinones, thiazepinones, diazepinones and sulfur analogs thereof
EP0107930B1 (en) *	1982-09-30	1990-11-28	A.H. ROBINS COMPANY, INCORPORATED (a Delaware corporation)	Fused aromatic oxazepinones and sulphur analogues thereof and their preparation and use in counteracting histamine
US5364620A (en)	1983-12-22	1994-11-15	Elan Corporation, Plc	Controlled absorption diltiazem formulation for once daily administration
US4654343A (en)	1985-10-31	1987-03-31	American Cyanamid Company	N-substituted-N[3-(1,2,4-triazolo[4,3-b]pyridazin-6-yl)phenyl]alkanamides, carbamates and ureas
US5023252A (en)	1985-12-04	1991-06-11	Conrex Pharmaceutical Corporation	Transdermal and trans-membrane delivery of drugs
JPH061779B2 (ja)	1987-07-31	1994-01-05	田中電子工業株式会社	半導体装置の製造方法
RO96410B1 (ro) *	1987-02-16	1989-03-02	Institutul Politehnic	Derivati de 1,4-benzoxazepinona si procedeu pentru prepararea lor
US4746655A (en)	1987-06-10	1988-05-24	A. H. Robins Company, Incorporated	Fused aromatic-spiropiperidine oxazepinones(and thiones)
US5001139A (en)	1987-06-12	1991-03-19	American Cyanamid Company	Enchancers for the transdermal flux of nivadipine
US4992445A (en)	1987-06-12	1991-02-12	American Cyanamid Co.	Transdermal delivery of pharmaceuticals
US4902514A (en)	1988-07-21	1990-02-20	Alza Corporation	Dosage form for administering nilvadipine for treating cardiovascular symptoms
DE4010488A1 (de)	1990-03-31	1991-10-02	Hoechst Ag	Benzoxazinderivate, verfahren zu ihrer herstellung und ihre verwendung zum behandeln oder zur prophylaxe von krankheiten
CA2044564A1 (en)	1990-06-28	1991-12-29	Quirico Branca	Amino acid derivatives
CN1060467A (zh)	1990-09-25	1992-04-22	武田药品工业株式会社	1，3-苯并嗪衍生物、其生产方法和用途
JPH04209692A (ja)	1990-12-03	1992-07-31	Asahi Glass Co Ltd	フォトクロミック材料
ATE152102T1 (de)	1991-05-10	1997-05-15	Takeda Chemical Industries Ltd	Pyridinderivate, deren herstellung und anwendung
US5939412A (en) *	1992-06-26	1999-08-17	Smithkline Beecham Corporation	Bicyclic fibrinogen antagonists
EP0593603B1 (en) *	1991-06-28	2002-11-20	Smithkline Beecham Corporation	Bicyclic fibrinogen antagonists
US5250679A (en) *	1991-10-18	1993-10-05	Genentech, Inc.	Nonpeptidyl platelet aggregation inhibitors having specificity for the GPIIb III.sub. receptor
US5663166A (en) *	1991-10-18	1997-09-02	Genentech, Inc.	Nonpeptidyl integrin inhibitors having specificity for the GPIIb IIIa receptor
US5272158A (en)	1991-10-29	1993-12-21	Merck & Co., Inc.	Fibrinogen receptor antagonists
JPH061779A (ja)	1992-02-06	1994-01-11	Wakamoto Pharmaceut Co Ltd	ベンズオキサジノン誘導体
JPH06107647A (ja)	1992-08-12	1994-04-19	Takeda Chem Ind Ltd	１，３−ベンゾオキサジン誘導体の製造法
US5442055A (en)	1992-11-13	1995-08-15	Tanabe Seiyaku Co., Ltd.	Azetidinone compound and process for preparation thereof
US6011150A (en)	1992-11-13	2000-01-04	Tanabe Seiyaku Co., Ltd.	Azetidinone compound and process for preparation thereof
GB9225860D0 (en)	1992-12-11	1993-02-03	Smithkline Beecham Plc	Novel treatment
GB9226302D0 (en)	1992-12-17	1993-02-10	Smithkline Beecham Plc	Pharmaceuticals
US5550229A (en)	1993-06-23	1996-08-27	Tanabe Seiyaku Co., Ltd.	Alkylation process for preparing azetidinone compound and starting compound therefor
DE19526173A1 (de)	1995-07-18	1997-01-30	Hoechst Ag	Polyfullerenaddukte, Verfahren zu ihrer regioselektiven Herstellung und deren Verwendung
JPH09157262A (ja)	1995-12-08	1997-06-17	Tanabe Seiyaku Co Ltd	アゼチジノン誘導体及びその合成中間体の製法
US5773186A (en)	1996-02-19	1998-06-30	Fuji Photo Film Co., Ltd.	Heat-sensitive recording material
GB9619492D0 (en)	1996-09-18	1996-10-30	Smithkline Beecham Plc	Novel treatment
JP2001526643A (ja)	1997-04-18	2001-12-18	スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー	５ｈｔ１ａ、５ｈｔ１ｂおよび５ｈｔ１ｄ受容体アンタゴニスト活性を合わせ持つ化合物を含む二環式アリールまたは二環式複素環
WO1998054135A1 (en)	1997-05-30	1998-12-03	Meiji Seika Kaisha, Ltd.	Nitrogenous heterocyclic compounds and hyperlipemia remedy containing the same
JP3964053B2 (ja)	1997-07-10	2007-08-22	三井化学株式会社	遷移金属化合物からなるオレフィン重合用触媒ならびに重合方法
DE69802204T2 (de)	1997-09-08	2002-04-18	Unilever N.V., Rotterdam	Verfahren zur verbesserung der enzymeaktivität
SK10922000A3 (sk)	1998-01-21	2001-03-12	Merck Sharp & Dohme Limited	Triazolopyridazínové deriváty, spôsob ich výroby, farmaceutický prostriedok s ich obsahom a ich použitie
EP1054877A1 (en) *	1998-02-11	2000-11-29	Du Pont Pharmaceuticals Company	Novel cyclic sulfonamide derivatives as metalloproteinase inhibitors
IL137720A0 (en)	1998-02-18	2001-10-31	Neurosearch As	Compounds and their use as positive ampa receptor modulators
CA2334836A1 (en)	1998-06-16	1999-12-23	Merck Sharp & Dohme Limited	Triazolo-pyridine derivatives as ligands for gaba receptors
EP1123297A1 (en)	1998-10-21	2001-08-16	Novo Nordisk A/S	New compounds, their preparation and use
MXPA01010176A (es)	1999-04-09	2002-03-27	Meiji Seika Kaisha	Compuestos heterociclicos que contienen nitrogeno y compuestos de benzamida y farmacos que los contienen.
US6627651B1 (en)	1999-05-07	2003-09-30	Takeda Chemical Industries, Ltd.	Cyclic compounds and uses thereof
US6121916A (en)	1999-07-16	2000-09-19	Eaton-Vorad Technologies, L.L.C.	Method and apparatus for recognizing stationary objects with a moving side-looking radar
WO2001016263A2 (en)	1999-08-27	2001-03-08	The Procter & Gamble Company	Controlled availability of formulation components, compositions and laundry methods employing same
AU6935700A (en)	1999-08-27	2001-03-26	Procter & Gamble Company, The	Color safe laundry methods employing zwitterionic formulation components
CA2382119A1 (en)	1999-08-27	2001-03-08	The Procter & Gamble Company	Fast-acting formulation components, compositions and laundry methods employing same
EP1206517A1 (en)	1999-08-27	2002-05-22	The Procter & Gamble Company	Color safe laundry methods employing cationic formulation components
WO2001016110A1 (en)	1999-08-27	2001-03-08	The Procter & Gamble Company	Bleach boosting components, compositions and laundry methods
TR200200471T2 (tr)	1999-08-27	2002-05-21	The Procter & Gamble Company	Kararlı formülasyon komponentleri, bunların kullanıldığı terkipler ve çamaşır yıkama metodları
JP2003508587A (ja)	1999-08-27	2003-03-04	ザ、プロクター、エンド、ギャンブル、カンパニー	安定性増強配合成分、これを用いた組成物および洗濯方法
IL135092A0 (en)	2000-03-15	2001-05-20	Kidron Agrochem Ltd	A composition for the control of pests
JP2003533525A (ja)	2000-05-15	2003-11-11	ダーウィン・ディスカバリー・リミテッド	Ｍｍｐおよびｔｎｆ阻害活性を有するヒドロキサム酸およびカルボン酸誘導体
EP1306373B1 (en)	2000-08-01	2007-05-16	Ono Pharmaceutical Co., Ltd.	3,4-dihydroisoquinoline derivative compounds and drugs containing these compounds as the active ingredient
JP2004521079A (ja)	2000-08-29	2004-07-15	ファルマシア・コーポレーション	アルファーｖベータ３アンタゴニストとして有用な二環式環系を含有する化合物
JP2002205992A (ja)	2000-11-08	2002-07-23	Takeda Chem Ind Ltd	二環式トリアゾロン誘導体およびそれを含有する除草剤
WO2002051441A1 (en)	2000-12-26	2002-07-04	Sankyo Company, Limited	Medicinal compositions containing diuretic and insulin resistance-improving agent
KR20030080087A (ko)	2001-03-09	2003-10-10	화이자 프로덕츠 인코포레이티드	항염증제로서의 트리아졸로피리딘
US6998408B2 (en)	2001-03-23	2006-02-14	Bristol-Myers Squibb Pharma Company	6-5, 6-6, or 6-7 Heterobicycles as factor Xa inhibitors
US20030114448A1 (en)	2001-05-31	2003-06-19	Millennium Pharmaceuticals, Inc.	Inhibitors of factor Xa
JP2005089298A (ja)	2001-09-18	2005-04-07	Japan Tobacco Inc	ナフタレン化合物及びその医薬用途
GB0124627D0 (en)	2001-10-15	2001-12-05	Smithkline Beecham Plc	Novel compounds
ES2291538T3 (es)	2001-11-13	2008-03-01	Schering Corporation	Antagonistas de nk1.
US7196108B2 (en)	2002-03-08	2007-03-27	Incyte San Diego Inc.	Bicyclic heterocycles for the treatment of diabetes and other diseases
JP2003277384A (ja)	2002-03-26	2003-10-02	Kyorin Pharmaceut Co Ltd	縮合ニ環式ピリジン誘導体
JP2003321461A (ja)	2002-04-25	2003-11-11	Kyorin Pharmaceut Co Ltd	縮合ビフェニル誘導体
US20040152696A1 (en) *	2002-08-01	2004-08-05	Euro-Celtique S.A.	2-substituted bicyclic benzoheterocyclic compounds and their use as sodium channel blockers
JP2006504665A (ja)	2002-08-13	2006-02-09	ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー	マトリックスメタロプロテイナーゼ阻害剤としてのアザイソキノリン誘導体
BR0313384A (pt)	2002-08-13	2005-07-12	Warner Lambert Co	Derivados de cromona como inibidores de metaloproteinases de matriz
US20040242572A1 (en)	2002-08-24	2004-12-02	Boehringer Ingelheim International Gmbh	New carboxamide compounds having melanin concentrating hormone antagonistic activity, pharmaceutical preparations comprising these compounds and process for their manufacture
DE10238865A1 (de)	2002-08-24	2004-03-11	Boehringer Ingelheim International Gmbh	Neue Carbonsäureamid-Verbindungen mit MCH-antagonistischer Wirkung, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
PA8579601A1 (es)	2002-08-30	2004-05-07	Pfizer Prod Inc	Compuestos antiinflamatorios de di y trifloruro-triazolo-piridinas
US7005523B2 (en)	2002-08-30	2006-02-28	Pfizer Inc.	Cycloalkyl-[4-(trifluorophenyl)-oxazol-5yl]-triazolo-pyridines
JPWO2004026292A1 (ja)	2002-09-20	2006-01-12	株式会社ツムラ	鎮咳薬
US20040204404A1 (en)	2002-09-30	2004-10-14	Robert Zelle	Human N-type calcium channel blockers
GB0223730D0 (en)	2002-10-11	2002-11-20	Novartis Ag	Organic compounds
WO2004037192A2 (en)	2002-10-22	2004-05-06	The Trustees Of The University Of Pennsylvania	Identification of antimycobacterial targets and the inhibition thereof as a treatment for infectious diseases
PL376822A1 (pl)	2002-11-07	2006-01-09	Merck & Co., Inc.	Pochodne fenyloalaniny jako inhibitory dipeptydylopeptydazy do leczenia lub zapobiegania cukrzycy
CN100430386C (zh)	2002-11-07	2008-11-05	默克公司	苯丙氨酸衍生物作为二肽基肽酶抑制剂用于治疗或预防糖尿病
CN1764460A (zh)	2003-01-13	2006-04-26	科泰克斯药品公司	由于睡眠剥夺和应激引起的认知下降的治疗方法
MY142651A (en)	2003-03-18	2010-12-15	Merck Sharp & Dohme	Biaryl substituted triazoles as sodium channel blockers
DE10317526A1 (de)	2003-04-16	2004-11-04	Degussa Ag	Verfahren zum Delignifizieren von ligninhaltigen Faserstoffen
CN100384856C (zh)	2003-04-17	2008-04-30	麦克公司	趋化因子受体活性调节剂杂环基环戊基四氢异喹啉和杂环基环戊基四氢吡啶并吡啶
MXPA05010174A (es)	2003-04-25	2005-11-08	Lundbeck & Co As H	Derivados de indol e indolina sustituidos.
WO2004101509A2 (en)	2003-05-06	2004-11-25	Case Western Reserve University	Functionalized benzoxazines, polymers and copolymers thereof
US20060148805A1 (en)	2003-07-01	2006-07-06	Meng Hsin Chen	Opthalmic compositions for treating ocular hypertension
AU2004260624A1 (en)	2003-07-21	2005-02-10	Solvay Pharmaceuticals Gmbh	Use of 3,7-diazabicyclo`3, 3,1 !nonane compounds for the treatment and/or prophylaxis of anti-arrhythmic events in male human patients
KR20060118398A (ko)	2003-08-05	2006-11-23	버텍스 파마슈티칼스 인코포레이티드	전압 개폐 이온 채널 억제제로서의 축합 피라미딘 화합물
US20050239767A1 (en)	2003-10-28	2005-10-27	Chan Michael K	Intermolecular SNAr of the heterocycle-activated nitro and fluoro groups-application in the synthesis of polyazamacrocyclic ligands
BRPI0417674A (pt)	2003-12-18	2007-03-20	Pfizer Prod Inc	método para tratar a inflamação aguda em animais, com inibidores de quinase map p38
SI1731512T1 (sl)	2004-03-05	2015-01-30	Nissan Chemical Industries, Ltd.	Z izoksazolinom substituirana benzamidna spojina in sredstvo za uravnavanje Ĺˇkodljivih organizmov
US7306631B2 (en)	2004-03-30	2007-12-11	The Procter & Gamble Company	Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof
GB0412986D0 (en)	2004-06-10	2004-07-14	Xention Discovery Ltd	Compounds
WO2006002470A1 (en)	2004-06-30	2006-01-12	Monash University	Chiral ligands for asymmetric catalysis
JP2006063064A (ja)	2004-07-27	2006-03-09	Takeda Chem Ind Ltd	受容体作動剤
JP2007297283A (ja)	2004-07-28	2007-11-15	Santen Pharmaceut Co Ltd	新規桂皮酸関連化合物
US7572783B2 (en) *	2004-08-13	2009-08-11	Amgen Inc.	Substituted benzofused heterocycles
US7521457B2 (en)	2004-08-20	2009-04-21	Boehringer Ingelheim International Gmbh	Pyrimidines as PLK inhibitors
JP2008510810A (ja)	2004-08-23	2008-04-10	メルクエンドカムパニーインコーポレーテッド	糖尿病の治療または予防のためのジペプチジルペプチダーゼ−ｉｖ阻害剤としての縮合トリアゾール誘導体
WO2006031676A2 (en)	2004-09-13	2006-03-23	Merck & Co., Inc.	Tricyclic anilide spirohydantoin cgrp receptor antagonists
TW200624431A (en)	2004-09-24	2006-07-16	Hoffmann La Roche	Phthalazinone derivatives, their manufacture and use as pharmaceutical agents
WO2006048727A1 (en)	2004-11-02	2006-05-11	Pfizer Products Inc.	Piperazinylphenalkyl lactam/amine ligands for the 5ht1b receptor
JP2006203875A (ja)	2004-12-24	2006-08-03	Matsushita Electric Ind Co Ltd	受信装置
WO2006091897A2 (en)	2005-02-25	2006-08-31	Adenosine Therapeutics, Llc	Derivatives of 8-substituted xanthines
TW200643015A (en)	2005-03-11	2006-12-16	Akzo Nobel Nv	2-(4-oxo-4H-quinazolin-3-yl)acetamide derivatives
EP1874753A2 (en) *	2005-04-14	2008-01-09	Smithkline Beecham Corporation	Compounds, compositions and methods
AR056317A1 (es)	2005-04-20	2007-10-03	Xenon Pharmaceuticals Inc	Compuestos de oxindol y composicion farmaceutica
CA2960117C (en)	2005-05-17	2018-01-30	Sarcode Bioscience Inc.	Lfa-1 antagonists for the treatment of eye disorders
TW200714597A (en)	2005-05-27	2007-04-16	Astrazeneca Ab	Chemical compounds
US7572807B2 (en)	2005-06-09	2009-08-11	Bristol-Myers Squibb Company	Heteroaryl 11-beta-hydroxysteroid dehydrogenase type I inhibitors
TW200726765A (en)	2005-06-17	2007-07-16	Bristol Myers Squibb Co	Triazolopyridine cannabinoid receptor 1 antagonists
WO2006138549A1 (en)	2005-06-17	2006-12-28	Wyeth	Tricyclic compounds useful as serotonin inhibitors and 5-ht1a agonists and antagonists
US7632837B2 (en)	2005-06-17	2009-12-15	Bristol-Myers Squibb Company	Bicyclic heterocycles as cannabinoid-1 receptor modulators
WO2007004028A2 (en)	2005-06-30	2007-01-11	Ranbaxy Laboratories Limited	Processes for the preparation of penems and its intermediate
US8932641B2 (en)	2005-08-26	2015-01-13	Amnos Co., Ltd.	Dried amnion and method for drying treatment of amnion
WO2007038138A2 (en)	2005-09-21	2007-04-05	Incyte Corporation	Amido compounds and their use as pharmaceuticals
CA2623026A1 (en)	2005-09-23	2007-04-05	Schering Corporation	Fused tetracyclic mglur1 antagonists as therapeutic agents
WO2007047604A2 (en)	2005-10-18	2007-04-26	Elixir Pharmaceuticals, Inc.	Sirt1 inhibition
TW200804290A (en)	2005-11-15	2008-01-16	Astrazeneca Ab	Compounds and uses thereof
AU2006316627A1 (en)	2005-11-18	2007-05-31	Merck Sharp & Dohme Corp.	Spirolactam aryl CGRP receptor antagonists
WO2007061696A2 (en)	2005-11-18	2007-05-31	Merck & Co., Inc.	Spirolactam bicyclic cgrp receptor antagonists
TW200734342A (en)	2005-12-15	2007-09-16	Astrazeneca Ab	New compounds for the treatment of cardiac arrhythmias
CN101330914A (zh)	2005-12-16	2008-12-24	爱尔康公司	使用alk5调节剂控制眼内压
US8013073B2 (en)	2005-12-30	2011-09-06	Chevron Oronite Company Llc	Method for preparing polyolefins containing vinylidine end groups using nonaromatic heterocyclic compounds
JP2009531390A (ja)	2006-03-31	2009-09-03	ノバルティスアクチエンゲゼルシャフト	有機化合物
JP5528699B2 (ja) *	2006-05-16	2014-06-25	武田薬品工業株式会社	縮合複素環化合物およびその用途
CN101500575A (zh)	2006-06-12	2009-08-05	沃泰克斯药物股份有限公司	可用作离子通道调控剂的噻吩并嘧啶
US20080011523A1 (en)	2006-06-29	2008-01-17	Packard Thomas G	Rotor energy augmented vehicle
WO2008005338A1 (en)	2006-06-29	2008-01-10	Arena Pharmaceuticals, Inc.	Modulators of the histamine h3-receptor useful for the treatment of disorders related thereto
CN101541783B (zh)	2006-06-30	2014-10-01	苏尼西斯制药有限公司	吡啶酮基pdk1抑制剂
WO2008007661A1 (en) *	2006-07-11	2008-01-17	Takeda Pharmaceutical Company Limited	Tricyclic heterocyclic compound and use thereof
US20100035756A1 (en)	2006-07-12	2010-02-11	Syngenta Limited	Triazolophyridine derivatives as herbicides
US8217177B2 (en)	2006-07-14	2012-07-10	Amgen Inc.	Fused heterocyclic derivatives and methods of use
PE20080403A1 (es)	2006-07-14	2008-04-25	Amgen Inc	Derivados heterociclicos fusionados y metodos de uso
NZ574905A (en)	2006-08-22	2011-12-22	Ranbaxy Lab Ltd	Matrix metalloproteinase inhibitors
EP2068869A4 (en)	2006-10-06	2011-05-25	Abbott Lab	NEW IMIDAZOTHIAZOLE AND IMIDAZOXAZOLE
WO2008118141A2 (en)	2006-10-17	2008-10-02	Acadia Pharmaceuticals Inc.	Use of cannabinoid modulating compounds in combination with other therapeutic compounds for adjunctive therapy
AR063527A1 (es)	2006-10-23	2009-01-28	Cephalon Inc	Derivados biciclicos fusionados de 2,4-diaminopirimidina como inhibidores de alk y c-met
SI2343286T1 (sl)	2006-10-28	2015-05-29	Methylgene Inc.	Derivati dibenzo(b,f)(1,4) oksazepina kot inhibitorji histonske deacetilaze
US20100099676A1 (en)	2006-11-02	2010-04-22	Shionogi & Co., Ltd.	Sulfonylurea derivative capable of selectively inhibiting mmp-13
US20080153840A1 (en)	2006-12-21	2008-06-26	Luiz Belardinelli	Reduction of cardiovascular symptoms
US8076350B2 (en)	2006-12-22	2011-12-13	Abbott Laboratories	Spirocyclic azaadamantane derivatives and methods of use
AR065081A1 (es)	2007-01-29	2009-05-13	Xenon Pharmaceuticals Inc	Compuestos de quinazolinona y pirimidona fusionados y composicion farmaceutica
AU2008219723A1 (en)	2007-02-28	2008-09-04	Merck Sharp & Dohme Corp.	Substituted benzodiazepinones, benzoxazepinones and benzothiazepinones as sodium channel blockers
WO2008108445A1 (ja)	2007-03-07	2008-09-12	Takeda Pharmaceutical Company Limited	ベンゾオキサゼピン誘導体およびその用途
GB0706072D0 (en)	2007-03-28	2007-05-09	Sterix Ltd	Compound
CN101657198A (zh) *	2007-04-12	2010-02-24	Cv医药有限公司	增强胰岛素分泌的雷诺嗪
WO2008128086A1 (en)	2007-04-12	2008-10-23	Cv Therapeutics, Inc.	Ranolazine for enhancing insulin secretion
WO2008134553A1 (en)	2007-04-26	2008-11-06	Xenon Pharmaceuticals Inc.	Methods of using bicyclic compounds in treating sodium channel-mediated diseases
WO2008144483A2 (en) *	2007-05-18	2008-11-27	Armgo Pharma, Inc.	Agents for treating disorders involving modulation of ryanodine receptors
US8188083B2 (en)	2007-06-28	2012-05-29	Abbott Laboratories	Triazolopyridazines
US20090012103A1 (en) *	2007-07-05	2009-01-08	Matthew Abelman	Substituted heterocyclic compounds
US20090036425A1 (en)	2007-08-02	2009-02-05	Pfizer Inc	Substituted bicyclolactam compounds
WO2009026444A1 (en)	2007-08-22	2009-02-26	President And Fellows Of Harvard College	Ryanodine channel binders and uses thereof
CN101848896A (zh)	2007-09-12	2010-09-29	惠氏有限责任公司	作为组胺-3拮抗剂的异喹啉基和异吲哚啉基衍生物
US8119658B2 (en)	2007-10-01	2012-02-21	Bristol-Myers Squibb Company	Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors
US8293763B2 (en)	2007-12-19	2012-10-23	Genentech, Inc.	8-anilinoimidazopyridines and their use as anti-cancer and/or anti-inflammatory agents
PE20091339A1 (es)	2007-12-21	2009-09-26	Glaxo Group Ltd	Derivados de oxadiazol con actividad sobre receptores s1p1
EP2231669A1 (en)	2008-01-09	2010-09-29	The U.S.A. As Represented By The Secretary, Department Of Health And Human Services	Phosphodiesterase inhibitors
BRPI0908428A2 (pt)	2008-02-06	2015-12-08	Gilead Sciences Inc	uso de ranozalina para tratar a dor.
RU2010137862A (ru)	2008-02-13	2012-03-20	ЭЙСАЙ Ар энд Ди МЕНЕДЖМЕНТ КО., ЛТД. (JP)	Производное бициклоамина
JP2009286773A (ja)	2008-03-14	2009-12-10	Bayer Cropscience Ag	殺虫性縮環式アリール類
WO2009137499A1 (en)	2008-05-05	2009-11-12	Envivo Pharmaceuticals, Inc.	Inhibitors of histone deacetylase
WO2009137462A2 (en)	2008-05-05	2009-11-12	Envivo Pharmaceuticals, Inc.	Methods for treating cognitive disorders using inhibitors of histone deacetylase
DE102008024182A1 (de)	2008-05-19	2009-11-26	Merck Patent Gmbh	Verbindungen für organische elektronische Vorrichtung
CN102089297A (zh)	2008-06-06	2011-06-08	雅培制药有限公司	新的1,2,4-噁二唑化合物和其使用方法
US8569298B2 (en)	2008-06-17	2013-10-29	Astrazeneca Ab	Pyridine compounds
EP2307027A4 (en)	2008-07-11	2012-08-15	Neumedics	TETRACYCLINE DERIVATIVES WITH REDUCED ANTIBIOTIC ACTIVITY AND NEUROPROTECTIVE PROPERTIES
WO2010018686A1 (ja)	2008-08-12	2010-02-18	日本曹達株式会社	含窒素ヘテロ環誘導体および農園芸用殺菌剤
CN102186812A (zh)	2008-08-18	2011-09-14	宇部兴产株式会社	制备氟烷基芳基亚磺酰基化合物及其氟化的化合物的方法
US20100056536A1 (en)	2008-09-04	2010-03-04	Charles Antzelevitch	Method of treating atrial fibrillation
WO2010053757A1 (en) *	2008-10-29	2010-05-14	Gilead Palo Alto, Inc.	2 -oxoquinoxalin blockers of the late sodium channel
US20100113514A1 (en) *	2008-10-30	2010-05-06	Gilead Palo Alto, Inc.	Fused heterocyclic compounds as ion channel modulators
WO2010056527A2 (en) *	2008-10-30	2010-05-20	Gilead Palo Alto, Inc.	Fused heterocyclic compounds as ion channel modulators
WO2010056865A1 (en) *	2008-11-14	2010-05-20	Gilead Palo Alto, Inc.	Quinoline derivatives as ion channel modulators
WO2010068461A1 (en) *	2008-11-25	2010-06-17	Gilead Palo Alto, Inc.	Co-administration of ranolazine and cardiac glycosides
US9040508B2 (en)	2008-12-08	2015-05-26	Vm Pharma Llc	Compositions of protein receptor tyrosine kinase inhibitors
CN102307871A (zh)	2008-12-08	2012-01-04	西特里斯药业公司	作为沉默调节蛋白调节剂的异吲哚啉酮和相关的类似物
JP5271069B2 (ja)	2008-12-24	2013-08-21	三和シヤッター工業株式会社	開閉装置
PT2385938E (pt) *	2009-01-12	2015-06-02	Pfizer Ltd	Derivados de sulfonamida
FR2943342B1 (fr)	2009-03-20	2011-03-04	Servier Lab	Nouveaux derives de benzothiadiazepines,leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
MX2011010132A (es)	2009-03-27	2011-10-14	Presidio Pharmaceuticals Inc	Inhibidores de anillo fusionado de hepatitis c.
WO2010118208A1 (en) *	2009-04-09	2010-10-14	Exelixis, Inc.	Benzoxazepin-4- (5h) -yl derivatives and their use to treat cancer
EA025824B1 (ru)	2009-07-27	2017-02-28	Джилид Сайэнс, Инк.	Конденсированные гетероциклические соединения в качестве модуляторов ионных каналов
RS53164B (sr)	2009-09-28	2014-06-30	F. Hoffmann-La Roche Ag	Jedinjenja benzoksazepin pi3k inhibitora i njihovo korišćenje u lečenju raka
WO2011042920A1 (en)	2009-10-07	2011-04-14	Decode Genetics Ehf	Genetic variants indicative of vascular conditions
WO2011056985A2 (en)	2009-11-04	2011-05-12	Gilead Sciences, Inc.	Substituted heterocyclic compounds
CN102791687B (zh)	2009-12-18	2015-02-11	北京凯因科技股份有限公司	C型肝炎病毒复制的新型抑制剂
TWI508726B (zh)	2009-12-21	2015-11-21	Gilead Sciences Inc	治療心房纖維性顫動之方法
ES2529119T3 (es)	2010-07-02	2015-02-17	Gilead Sciences, Inc.	Compuestos heterocíclicos condensados como moduladores de canales iónicos
WO2012019071A1 (en) *	2010-08-06	2012-02-09	The Trustees Of Columbia University In The City Of New York	Methods of preventing and treating sarcopenia
WO2012019076A1 (en) *	2010-08-06	2012-02-09	The Trustees Of Columbia University In The City Of New York	Compositions and methods for preventing and treating cardiac ischemia/reperfusion injury
WO2012037105A1 (en) *	2010-09-14	2012-03-22	The Trustees Of Columbia University In The City Of New York	Methods of treating, ameliorating or preventing stress-induced neuronal disorders and diseases
WO2012036233A1 (ja)	2010-09-17	2012-03-22	塩野義製薬株式会社	メラニン凝集ホルモン受容体アンタゴニスト活性を有する縮合へテロ環誘導体
WO2012038813A1 (en)	2010-09-21	2012-03-29	Purdue Pharma L.P.	Buprenorphine analogs
US8999967B2 (en)	2010-09-29	2015-04-07	Presidio Pharmaceuticals, Inc.	Tricyclic fused ring inhibitors of hepatitis C
EP2643316A2 (en) *	2010-11-24	2013-10-02	Exelixis, Inc.	Benzoxazepines as inhibitors of p13k/mtor and methods of their use and manufacture
JP5675428B2 (ja)	2011-02-25	2015-02-25	サンドビック株式会社	ベルトプレス装置
JP6001635B2 (ja)	2011-03-21	2016-10-05	エフ．ホフマン−ラロシュアーゲーＦ．Ｈｏｆｆｍａｎｎ−ＬａＲｏｃｈｅＡｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ	ＰＩ３Ｋｐ１１０δに選択的なベンゾオキサゼピン化合物及び使用方法
KR20140033377A (ko)	2011-05-10	2014-03-18	길리애드 사이언시즈, 인코포레이티드	나트륨 채널 조절제로서의 융합된 헤테로시클릭 화합물
US8753674B2 (en)	2011-06-03	2014-06-17	Signpath Pharma Inc.	Liposomal mitigation of drug-induced long QT syndrome and potassium delayed-rectifier current
NO3175985T3 (it)	2011-07-01	2018-04-28
TWI567061B (zh)	2011-07-01	2017-01-21	吉李德科學股份有限公司	用於治療成癮之化合物
TW201837023A (zh)	2011-07-01	2018-10-16	美商基利科學股份有限公司	作為離子通道調節劑之稠合雜環化合物
JP2014531454A (ja)	2011-09-21	2014-11-27	ギリアードサイエンシーズ，インコーポレイテッド	グルカゴン分泌を減少させるナトリウムチャネルブロッカー
WO2013097052A1 (en)	2011-12-30	2013-07-04	Abbott Laboratories	Bromodomain inhibitors
US8623860B2 (en)	2011-12-30	2014-01-07	Boehringer Ingelheim International Gmbh	Azetidine derivatives, pharmaceutical compositions and uses thereof
AU2013203252B2 (en)	2012-01-27	2015-08-20	Gilead Sciences, Inc.	Combination therapies using late sodium ion channel blockers and potassium ion channel blockers
BR112014000049A2 (pt)	2012-03-27	2017-02-07	Bayer Ip Gmbh	pirrolotriazinas substituídas com hidroximelilarilo e sua utilização
ES2805341T3 (es)	2012-06-13	2021-02-11	Acesion Pharma Aps	Composiciones farmacéuticas para terapia de combinación
WO2014134419A1 (en)	2013-03-01	2014-09-04	Gilead Sciences, Inc.	Use of ikach blockers for the treatment of cardiac diseases
TW201613908A (en)	2014-02-13	2016-04-16	Gilead Sciences Inc	Solid forms of an ion channel modulator
CN104844535A (zh)	2014-02-13	2015-08-19	吉利德科学公司	用于制备稠合杂环离子通道调节剂的方法

2012
- 2012-06-28 TW TW107102252A patent/TW201837023A/zh unknown
- 2012-06-28 TW TW101123291A patent/TWI478908B/zh not_active IP Right Cessation
- 2012-06-28 UY UY0001034171A patent/UY34171A/es not_active Application Discontinuation
- 2012-06-28 TW TW105120804A patent/TWI622583B/zh not_active IP Right Cessation
- 2012-06-28 TW TW104100530A patent/TWI549944B/zh not_active IP Right Cessation
- 2012-06-29 DK DK12735402.5T patent/DK2726466T3/en active
- 2012-06-29 US US13/538,847 patent/US8586732B2/en active Active
- 2012-06-29 PT PT127354025T patent/PT2726466T/pt unknown
- 2012-06-29 ES ES16169386T patent/ES2790633T3/es active Active
- 2012-06-29 PL PL12735402T patent/PL2726466T3/pl unknown
- 2012-06-29 SI SI201230579A patent/SI2726466T1/sl unknown
- 2012-06-29 BR BR112013032361A patent/BR112013032361A2/pt not_active Application Discontinuation
- 2012-06-29 MX MX2013014846A patent/MX336810B/es active IP Right Grant
- 2012-06-29 HU HUE12735402A patent/HUE029398T2/en unknown
- 2012-06-29 AU AU2012279236A patent/AU2012279236B2/en not_active Ceased
- 2012-06-29 KR KR1020137033295A patent/KR101608927B1/ko not_active Expired - Fee Related
- 2012-06-29 ES ES16169320T patent/ES2797128T3/es active Active
- 2012-06-29 EP EP16169314.8A patent/EP3101013B1/en active Active
- 2012-06-29 EA EA201391639A patent/EA027356B1/ru not_active IP Right Cessation
- 2012-06-29 EP EP16169306.4A patent/EP3085694B1/en active Active
- 2012-06-29 KR KR1020167008350A patent/KR20160040734A/ko not_active Withdrawn
- 2012-06-29 CN CN201280042528.4A patent/CN103857659B/zh not_active Expired - Fee Related
- 2012-06-29 CA CA2838223A patent/CA2838223A1/en not_active Abandoned
- 2012-06-29 AP AP2013007300A patent/AP2013007300A0/xx unknown
- 2012-06-29 CN CN201611165938.4A patent/CN106995415A/zh active Pending
- 2012-06-29 EP EP16169320.5A patent/EP3098218B1/en active Active
- 2012-06-29 NZ NZ618691A patent/NZ618691A/en not_active IP Right Cessation
- 2012-06-29 ES ES16169306T patent/ES2792864T3/es active Active
- 2012-06-29 NZ NZ716245A patent/NZ716245A/en not_active IP Right Cessation
- 2012-06-29 ES ES16169314T patent/ES2842433T3/es active Active
- 2012-06-29 EP EP12735402.5A patent/EP2726466B1/en active Active
- 2012-06-29 MD MDA20130095A patent/MD4371C1/ro not_active IP Right Cessation
- 2012-06-29 PE PE2013002817A patent/PE20140690A1/es active IP Right Grant
- 2012-06-29 EP EP16169386.6A patent/EP3085696B1/en active Active
- 2012-06-29 AR ARP120102370A patent/AR086828A1/es unknown
- 2012-06-29 HR HRP20160952TT patent/HRP20160952T1/hr unknown
- 2012-06-29 RS RS20160623A patent/RS55024B1/sr unknown
- 2012-06-29 JP JP2014519190A patent/JP5889407B2/ja not_active Expired - Fee Related
- 2012-06-29 UA UAA201314145A patent/UA115529C2/uk unknown
- 2012-06-29 ME MEP-2016-152A patent/ME02546B/me unknown
- 2012-06-29 PH PH1/2013/502549A patent/PH12013502549B1/en unknown
- 2012-06-29 EP EP16169333.8A patent/EP3088395B1/en active Active
- 2012-06-29 WO PCT/US2012/045086 patent/WO2013006485A1/en not_active Ceased
- 2012-06-29 ES ES12735402.5T patent/ES2583415T3/es active Active
- 2012-06-29 ES ES16169333T patent/ES2792866T3/es active Active
- 2012-06-29 EA EA201790417A patent/EA201790417A3/ru unknown
2013
- 2013-03-07 US US13/789,469 patent/US8697863B2/en active Active
- 2013-09-26 US US14/038,646 patent/US9193694B2/en active Active
- 2013-11-29 ZA ZA2013/08981A patent/ZA201308981B/en unknown
- 2013-12-13 CO CO13291981A patent/CO6821960A2/es not_active Application Discontinuation
- 2013-12-13 CR CR20130658A patent/CR20130658A/es unknown
- 2013-12-16 CL CL2013003598A patent/CL2013003598A1/es unknown
- 2013-12-16 EC ECSP13013083 patent/ECSP13013083A/es unknown
- 2013-12-18 IL IL230022A patent/IL230022B/en active IP Right Grant
2015
- 2015-10-01 US US14/872,787 patent/US9598435B2/en active Active
- 2015-12-28 JP JP2015255906A patent/JP6273250B2/ja not_active Expired - Fee Related
2016
- 2016-05-11 US US15/152,231 patent/US9676760B2/en active Active
- 2016-08-08 SM SM201600271T patent/SMT201600271B/it unknown
- 2016-08-18 CY CY20161100816T patent/CY1117915T1/el unknown
- 2016-12-08 HK HK16113998.7A patent/HK1225726A1/en unknown
- 2016-12-08 HK HK16113997.8A patent/HK1225725A1/en unknown
- 2016-12-08 HK HK16113995.0A patent/HK1225724A1/en unknown
- 2016-12-15 HK HK16114300.8A patent/HK1226061A1/en unknown
- 2016-12-15 HK HK16114299.1A patent/HK1226060A1/en unknown
2018
- 2018-01-08 IL IL256779A patent/IL256779A/en unknown

Also Published As

Publication number	Publication date
NZ618691A (en)	2016-05-27
AU2012279236B2 (en)	2015-05-14
HRP20160952T1 (hr)	2016-10-07
MX2013014846A (es)	2014-03-31
ES2792864T3 (es)	2020-11-12
DK2726466T3 (en)	2016-09-05
EP3085696A1 (en)	2016-10-26
US20140135317A1 (en)	2014-05-15
US20160347744A1 (en)	2016-12-01
US8697863B2 (en)	2014-04-15
MX336810B (es)	2016-02-03
EP2726466A1 (en)	2014-05-07
EP3101013A1 (en)	2016-12-07
AU2012279236A1 (en)	2013-04-04
HUE029398T2 (en)	2017-02-28
EA201790417A2 (ru)	2017-07-31
EP3098218B1 (en)	2020-03-25
PE20140690A1 (es)	2014-06-19
EP3101013B1 (en)	2020-10-21
CN103857659B (zh)	2017-02-15
CA2838223A1 (en)	2013-01-10
US9676760B2 (en)	2017-06-13
AP2013007300A0 (en)	2013-12-31
US20160096846A1 (en)	2016-04-07
ES2790633T3 (es)	2020-10-28
JP2014522847A (ja)	2014-09-08
JP6273250B2 (ja)	2018-01-31
ME02546B (me)	2017-02-20
US8586732B2 (en)	2013-11-19
IL230022A0 (en)	2014-03-06
EP3088395A1 (en)	2016-11-02
US20130184255A1 (en)	2013-07-18
CL2013003598A1 (es)	2014-07-11
KR101608927B1 (ko)	2016-04-04
MD4371B1 (ro)	2015-09-30
US9598435B2 (en)	2017-03-21
UA115529C2 (uk)	2017-11-27
TW201712000A (zh)	2017-04-01
PH12013502549A1 (en)	2014-02-10
WO2013006485A1 (en)	2013-01-10
ES2842433T3 (es)	2021-07-14
PL2726466T3 (pl)	2017-07-31
AR086828A1 (es)	2014-01-22
SI2726466T1 (sl)	2016-07-29
US9193694B2 (en)	2015-11-24
HK1225724A1 (en)	2017-09-15
EP3098218A1 (en)	2016-11-30
EP3088395B1 (en)	2020-03-25
HK1225725A1 (en)	2017-09-15
CO6821960A2 (es)	2013-12-31
BR112013032361A2 (pt)	2016-09-06
EA027356B1 (ru)	2017-07-31
US20130012492A1 (en)	2013-01-10
PH12013502549B1 (en)	2019-02-06
TWI478908B (zh)	2015-04-01
CN106995415A (zh)	2017-08-01
EP3085694A1 (en)	2016-10-26
EP3085696B1 (en)	2020-03-04
HK1225726A1 (en)	2017-09-15
TW201531466A (zh)	2015-08-16
CR20130658A (es)	2014-04-15
TW201305120A (zh)	2013-02-01
RS55024B1 (sr)	2016-11-30
UY34171A (es)	2013-01-31
ES2797128T3 (es)	2020-12-01
JP5889407B2 (ja)	2016-03-22
HK1226061A1 (en)	2017-09-22
NZ716245A (en)	2017-07-28
MD4371C1 (ro)	2016-07-31
HK1226060A1 (en)	2017-09-22
TW201837023A (zh)	2018-10-16
TWI622583B (zh)	2018-05-01
PT2726466T (pt)	2016-07-28
MD20130095A2 (ro)	2014-04-30
EP3085694B1 (en)	2020-03-25
EA201391639A1 (ru)	2014-06-30
EA201790417A3 (ru)	2017-11-30
ECSP13013083A (es)	2014-01-31
ZA201308981B (en)	2016-02-24
IL230022B (en)	2018-11-29
KR20160040734A (ko)	2016-04-14
HK1196602A1 (zh)	2014-12-19
EP2726466B1 (en)	2016-05-25
CN103857659A (zh)	2014-06-11
JP2016041768A (ja)	2016-03-31
KR20140033413A (ko)	2014-03-18
TWI549944B (zh)	2016-09-21
IL256779A (en)	2018-03-29
ES2792866T3 (es)	2020-11-12
ES2583415T3 (es)	2016-09-20
CY1117915T1 (el)	2017-05-17

Publication	Publication Date	Title
SMT201600271B (it)	2016-08-31	BENZOSSAZEPINONI FUSI COME MODULATORI DI CANALl IONICI
LT2742151T (lt)	2018-02-12	Polimerazės kompozicija
BR112013022112A2 (pt)	2018-06-26	composição
DK2744810T4 (da)	2023-11-20	Tenofovir-alafenamid-hemifumarat
BR112013022102A2 (pt)	2018-06-26	composição
EP2715659A4 (en)	2014-11-12	ABOUT FEED
DK2686017T3 (da)	2019-10-07	Oftalmisk sammensætning
BR112014004395A2 (pt)	2017-03-28	composição
DK2769050T3 (da)	2021-05-17	Propsensor
DE102011100082A8 (de)	2013-01-10	Traygreifvorrichtung
BR112014000879A2 (pt)	2017-02-21	deflegmador
DK3272861T3 (da)	2020-03-23	Alpha-galactosidase-sammensætninger
EP2701512A4 (en)	2014-11-26	Aldosterone synthase inhibitors
CO6960543A2 (es)	2014-05-30	2-tiopirimidinonas
BR112013033808A2 (pt)	2017-02-14	composição
EP2723481A4 (en)	2014-12-17	FLOW COMPENSATOR
EP2730619A4 (en)	2015-02-18	COMPOSITION
DK3141251T3 (da)	2021-02-01	Koloskopi - forberedelse
PT2739276T (pt)	2019-05-27	Composição antisséptica
EP2708561A4 (en)	2014-09-24	BIO-PIN
BR112014007030A2 (pt)	2017-04-11	composição
EP2692796A4 (en)	2014-09-17	Composition
SI2734186T1 (sl)	2018-11-30	Sestavek
DE112012000958A5 (de)	2013-11-28	Handsäge
CO6920305A2 (es)	2014-04-10	Heterociclilpiri(mi)dinilpirazol